Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma [3]

Blood

Volumn 107, Issue 3, 2006, Pages 1240-

  Herling, Marco ^a   Rassidakis, George Z ^b   Vassilakopoulos, Theodoros P ^b   Medeiros, L Jeffrey ^b   Sarris, Andreas H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; LATENT MEMBRANE PROTEIN 1; VINBLASTINE; VIRUS RNA;

CANCER RADIOTHERAPY; CARDIOTOXICITY; CLASSICAL HODGKIN LYMPHOMA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; GROUPS BY AGE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LETTER; LUNG TOXICITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; RELAPSE; RNA HYBRIDIZATION; VIRUS INFECTION;

EID: 31544449118     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood.v107.3.1240.1240     Document Type: Letter

References (4)

1. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106:2444-2451.
2. Herling M, Rassidakis GZ, Medeiros LJ, et al. LMP-1 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum levels of IL-10, and clinical outcome. Clin Cancer Res. 2003;9:2114-2120.
3. Claviez A, Tiemann M, Luders H, et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with HL. J Clin Oncol. 2005;23:4048-4056.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339:1506-1514.